UBXN11 and endocrine system disorder: Areas of focus for this long-term analysis were endocrine disorders: 160/1,052 (15%) SOC versus 155/992 (16%) SOC+RT; musculoskeletal disorders: 112/1,052 (11%) SOC, 104/992 (10%) SOC+RT; blood and bone marrow disorders: 56/1,052 (5%) SOC, 49/992 (5%) SOC+RT; cardiovascular disorders: 46/1,052 (4%) SOC, 56/992 (6%) SOC+RT; renal disorders: 50/1,052 (5%) SOC, 52/992 (5%) SOC+RT; general disorders: 57/1,052 (5%) SOC, 43/992 (4%) SOC+RT; gastrointestinal disorders: 47/1,052 (4%) SOC, 52/992 (5%) SOC+RT; lab abnormalities: 49/1,052 (5%) SOC, 48/992 (5%) SOC+RT (Table I in S1 Text, S7 Fig).